Hikma Further Improves Its Environmental Performance In CDP Global Climate Change Report 2019
Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1/stable Moody’s and BB+/positive S&P), the multinational generic pharmaceutical company, has received a ‘B’ rating from the CDP Global Climate Change Report 2019, marking an improvement over the Company’s most recent score and placing it above the European CDP average. CDP is an independent, […]
Read More →
